Psychemedics Revenue, Profits - PMD Quarterly Income Statement

Add to My Stocks
$20.43 $0.23 (1.14%) PMD stock closing price Aug 18, 2017 (Closing)

Financial analysis of Psychemedics involves more than just checking the Psychemedics stock price, by looking at the financial statements of the company in detail. The income statement is a summary of the revenue, expenses and profitability (shown as Net Income) or lack of it. The income statement is generated for a specific period of time. The revenue decrease of $9.68M for 2017-Q2 impacts the PMD stock. Investors typically check year over year or quarter over quarter revenue growth. The Psychemedics profit and loss statement for 2017-Q2 shows a profit of $0.91M. Profits have reduced from $1.5M QoQ. Apart from this an investor should also check Psychemedics assets and Psychemedics free cash flow. View details of revenue and profits for Psychemedics for latest & last 40 quarters.

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec.2017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q32015 Q22015 Q1
Psychemedics Net Sales or Revenues
9.68M10.21M10.76M11.85M9.7M6.67M6.13M7.08M7M6.76M
Cost Of Goods Sold (COGS)5.08M4.89M4.38M4.74M4.49M3.92M3.49M3.62M3.73M3.41M
Psychemedics Gross Profit
4.61M5.31M6.42M7.1M5.2M2.73M2.67M3.45M3.26M3.33M
Research & Development Expense0.32M0.33M0.36M0.34M0.35M0.36M0.36M0.39M0.43M0.45M
Selling General & Admin Expense2.58M2.71M2.42M2.65M2.48M2.37M2.2M2.51M2.47M2.43M
Income Before Depreciation Depletion Amortization1.71M2.26M3.64M4.1M2.37M-0.12M0.55M0.35M0.45M
Depreciation Depletion Amortization----------
Non Operating Income---0.13M----0.03M-0.03M-0.03M-0.03M
Interest Expense0.01M0.02M-0.09M0.03M0.03M0.03M----
Psychemedics Pretax Income
1.7M2.24M3.6M4.07M2.33M-0.03M0.09M0.52M0.32M0.41M
Provision for Income Taxes0.79M0.74M1.24M1.36M0.7M-0.01M-0.09M-0.27M0.07M0.13M
Minority Interest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations0.91M1.5M2.36M2.71M1.63M-0.02M0.19M0.8M0.25M0.28M
Extraordinary Items & Discontinued Operations----------
Psychemedics Net Income (Profit/Loss)
0.91M1.5M2.36M2.71M1.63M-0.02M0.19M0.8M0.25M0.28M
Average Shares used to compute Diluted EPS5.34M5.56M5.49M5.51M5.45M5.42M5.42M5.43M5.41M5.4M
Average Shares used to compute Basic EPS5.34M5.56M5.49M5.46M5.44M5.42M5.42M5.42M5.4M5.38M
Income Before Nonrecurring Items0.91M1.5M2.36M2.71M1.63M-0.02M0.19M0.8M0.25M0.28M
Income from Nonrecurring Items----------
Psychemedics Earnings Per Share Basic Net
0.170.270.430.500.30-0.030.150.050.05
Psychemedics Earnings Per Share Diluted Net
0.160.270.430.490.30-0.030.150.050.05
EPS Diluted Before Nonrecurring Items0.160.270.430.490.30-0.030.150.050.05
Preferred Dividends Acc Pd----------
Dividends Common0.820.82--------
Dividend Per Share Common0.150.150.150.150.150.150.150.150.150.15
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Income statement for another ticker

It is very helpful to read a report on Psychemedics stock analysis. An investor must check the following items in an income statement:
  • Topline: A growing topline, as seen from the Psychemedics revenue chart, as is not the case with Psychemedics indicates a sagging business. One needs to compare the QoQ or YoY topline growth of PMD stock with its peers like AAC stock and QHC stock to see if the growth compares well with what can be expected for a company in that industry.
  • Bottom line: Most businesses like Psychemedics try to improve their bottom line by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.
The income statement is also called statement of revenue and expense. The financials along with Psychemedics historical stock prices provides a lot of details about the firm. .

Psychemedics Income Statement - Key Financial Ratios

PE ratio (price earnings ratio)
15.1330
PS ratio (
price sales ratio
)
2.5670
Operating margin
22.1
Net profit margin
14.7
Dividend yield
2.94%